Predictive Technology Group Inc (PRED)

[traderking60]

Predictive Technology Group, Inc. (PRED~$2.13)

Corporate phone # [phone] www.predtechgroup.com

www.predicttivebiotech.com

www.predictivelabs.com

Predictive Technology Group, Inc. , through its wholly owned subsidiaries , revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases onsets and progressions. PRED'S subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

Through its' wholly -owned subsidiaries, Predictive Therapeutics and Predictive Biotech, the company focuses on four main clinical categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products. In addition to Predictive Biotech's efforts to advance regenerative medicine. Predictive Therapeutics is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.

TOTAL PRODUCTIVITY LOSS IN EMPLOYED WOMEN WITH ENDOMETRIOSIS AVERAGES 6.3 HOURS/WEEK, WITH THE MAJORITY OF LOST PRODUCTIVITY DUE TO PRESENTEEISM, AND THE YEARLY TOTAL COST OF ENDOMETRIOSIS HAS BEEN ESTIMATED AT $22 BILLION IN THE USA (APRIL 2018).

Endometriosis is a chronic, complex, yet relatively common gynecological disorder, reportedly affecting >7 0 million adult and adolescent females worldwide.

Predictive Therapeutics (PRx) and Predictive biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.

PRx utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression. Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to determine which patients are subject to a greater risk of developing disease, and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time.

Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and may be useful in disease prevention. By understanding the genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.

The first expected diagnostic PRED, through its sub PRx, expects to commercialize is a genetic diagnostic for ENDOMETRIOSIS for the fertility market. PRx then will focus development resources on its proprietary genetic based diagnostics for scoliosis and degenerative disc disease.

NHP-07- First pharma/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk** as a companion diagnostic/prognostic is the only treatment protocol that may suppress/prevent development of endometriosis and its debilitating symptoms.

Predictive biotech develops and commercializes minimally manipulated allograft products from umbilical cord and placental tissue.

HUMAN CELL AND TISSUE PRODUCTS INCLUDE:

1.CoreCyte** is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord . CoreCyte** is processed to preserve the biological and structural integrity of Wharton's jelly for homologous use.

2.PolyCyte** is a minimally manipulated human tissue allograft suspension derived from the Wharton's jelly of the umbilical cord. PolyCyte** is processed to preserve the molecular profiles of cytokines, growth factors and proteins in Wharton's jelly for homologous use.
3.AmnioCyte Plus ** is a minimally manipulated human tissue allograft suspension derived from the extracellular matrix of the amniotic membrane. AmnioCyte Plus** is processed to preserve the cellular scaffolding proteins and cytokines in amniotic membrane for homologous use.

4. AmnioCyte** is a minimally manipulated human tissue allograft derived from amniotic fluid. AmnioCyte** is processed to preserve the molecular profile of cytokines, growth factors and proteins in amniotic fluid for homologous use.

We suggest if you want even more detailed information concerning all the additional research and development that you read the Quarterly Report (Feb 15, 2019) ending December 31, 2018. We also suggest that you visit their website and of course read the current news.

LET US TAKE A LOOK AT THE MANAGEMENT TEAM , DIRECTORS AND ADVISORY BOARD!

1.Mr, John Sorrentino~Chairman. VP and CEO of Pfizer Vaccine R&D~

2.Mr. Bradley Robinson~President. Previously President, Sagent Technologies, CEO/Co-Founder of Infusive Technologies and Director/Co-Founder of Specialized Health Products, Inc.

3. Mr. Michael Dey~Director. Executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs for Wyeth's Women's Health Care business. As President of Wyeth's WHC for 7 years. Dr Dey managed its global resources of more than $3 billion annually.

4.Mr. Simon Brewer~CFO~Served as CFO for Norbest and played integral role in the Company's sales growth to $150 million annually.

5.Mr. Paul Evans~COO~Prior he was head of all intellectual property matters for Vivint.

6.Orrin G Hatch~7 terms as U.S. Senator(42 years) from Utah

6.Mr. Barhorst ~ Financial Advisory Board ~Chair of The California State University Foundation . He retired as President and CEO of ING Financial ,LLC

7. Mr. Jay Moyes~Director~ CFO of publicly traded biomaterials company, Amedica Corp, now SINTX Tech. Also CFO during 14 year tenure at publicly traded Myraid Genetics. Myraid transitioned from 10 to more than 900 employees,he was instrumental in raising more than $500 million in public and private finance .

8.Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale (Scientific Advisory Board)

9. Dr. kenneth Ward ~Chairman and CEO of Juneau Biosciences (Scientific Advisory Board)

Note: PRED recently acquired 70% of this company. See recent presser.

10. Mr. Eric Olson~Executive VP and CEO of Predictive Biotech.~ Prior CEO of Skeletal kinetics which developed and commercialized synthetic bone substitutes for Orthopedic and Spinal applications.

11. Dr. John Nelson~Chief Medical Officer~Served as President of the AMA and served on the Advisory Committee to the Director of the National institute of Health (NIH).

12. Mr Tim Lacy~President~27 years in the healthcare industry. Key role in the commercialization of PRED products and services.

NOTE: All directors and Advisory Board members do not receive any payments for their service except for recently offered 1 year options to up to 10,000,000 shares of restricted common shares at $2.07. These option only have a one year term limit to exercise. One person does have a small amount of stock options at .50 and the balance at $2.70, but only have 1 year exercise period as well.


Select financial data:

The reporting revenue derived from HCT/Ps. The Company operates in two reportable segments. HCT/Ps and diagnostics and therapeutics. Predictive Biotech's HCT/Ps are processed in the company's FDA registered lab. This segment HCT/Ps manipulates tissue products and are prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factor and general cytokines and are intended for homologous use. Predictive Technology's diagnostics and therapeutics uses data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics.

Revenue year-ending fiscal 18 ~ $16.2 million and net loss of $12 million.

Revenue for the 6 months ending 12/31/18 ( fiscal 19) revenues equaled $18.8 million and net loss $4.1 million. The total equity for the 6 months ending Dec 31, 2018 equaled $103 million and based upon 247 million shares outstanding. At the time of filing during Feb 2019 the outstanding shares equaled 271 million.

As of April 4, 2019 the total outstanding shares equaled 272 million. This number includes any shares used to acquire 70% of Juneau Bioscience which holds licensed technology supporting its ARTGuide** test for endometriosis and other genetic causes of infertility.

Note: Juneau had revenues not included within Dec 31, 2018 six month numbers. The stand alone revenue equaled $2.5 million for calendar year ending Dec 31, 2018 with losses of $2.4 million.

On or about March 26th 2019 PRED completes acquisition of Taueret Laboratories. The addition of CAP/CLIA lab and experienced diagnostics team form an unparalleled molecular clinical and research facility to accelerate new product development, commercialization and scale.

This $10 million dollar acquisition was paid with $1.2 million in restricted common stock and $8.5 million to be paid on or before Dec 31, 2020.

In conjunction with the acquisition, PRED invested $4.2 million in new laboratory instrumentation and resources to bolster capabilities in the 15,000 square-foot laboratory and administrative campus, which now contains all necessary infrastructure for the Company's clinical operations.

Taueret Laboratories is a privately held molecular lab focusing on human infertility , women's health, and childhood diseases and performs genetic testing using state-of-art-instrumentation.

Note: On March 28, 2019 PRED announced the completed build out of a new production lab and R&D facility for its sub company, Predictive Biotech. The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah's campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods.


Overview:

Management comments concerning 6 month financial reporting ending Dec 31, 2018 ( fiscal 2019). Bradley C. Robinson, CEO of PRED announced the most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth. He goes on to say that it puts PRED on a run rate exceeding $40 million for fiscal 2019. In addition the company generated $2 million in positive cash flow from operations for the past 6 months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. At the end of the second Q the company had $2.6 million cash on hand and no-long term debt.

Please keep in mind since that announcement was made there have been many additions to the growth profile of PRED.

We anticipate additional updates and projections from management near term.

BOTTOM-LINE: FROM ALL INDICATIONS WE ARE WITNESSING A HIGH TECH BIOTECH COMPANY BEING FORMED. THE CLUES SHOULD BE VERY EASY TO SPOT. THE MANAGEMENT TEAM, DIRECTORS AND ADVISORY BOARD INDICATES SERIOUS COMMITMENT FROM HIGHLY SUCCESSFUL INDIVIDUALS THAT APPEAR TO HAVE FORMED A VERY TIGHT-KNIT ORGANIZATION THAT HAS A WELL THOUGHT OUT PLAN TO GROW RAPIDLY INTO A REVENUE DRIVEN BIOTECH AND SCIENCE ORIENTED COMPANY. THE CONNECTIONS THAT MANAGEMENT MUST HAVE LEADS US TO BELIEVE THAT ADDITIONAL ACQUISITION ARE FORTHCOMING! WE BELIEVE THAT FILING THEIR FORM 10 TO LIST UPON THE NASDAQ IS ALSO IN THE WORKS. ONCE THIS COMPANY LISTS IT IS OBVIOUS THAT REGIONAL AND MAYBE LARGER FIRMS WILL FOLLOW THE SUCCESS OF PRED!

ONE MUST ASSUME THAT AS THIS COMPANY GROWS ADDITIONAL FUNDING WILL BE NEEDED SO IT A NATURAL ROAD MAP THAT INVESTMENT BANKING FIRMS WILL STEP UP TO PLATE.

WE BELIEVE THAT PRED IS IN THE EARLY STAGES OF EXPLOSIVE GROWTH VIA ORGANIC AND BY ACQUISITION.

ALL THE PIECES OF THIS PUZZLE HAVE BEEN SET IN MOTION AND THE VISIONARY INVESTOR TYPE SHOULD BE ABLE TO GLEEN WITH A GREAT DEGREE OF CERTAINTY THAT PRED IS ON THE LAUCH PAD!

(

We have a strong feeling that this opportunity may very well surpass all expectations during the next 3-6 months. We rate PRED with a very STRONG BUY RECOMMENDATION with potential rapid share appreciation.



WE WISH TO THANK ALL INVESTORS THAT HAVE BEEN FOLLOWING OUR STOCK RECOMMENDATIONS FOR THE PAST 35 YEARS. S. A. ADVISORY HAS ALWAYS TRIED TO BE AS HONEST AND ETHICAL WITH RESPECT TO OUR HONEST OPINION AND RECOMMENDATIONS.

WE MAY BUY, SELL AND OR HOLD AT OUR OWN DISCRETION .We currently own shares in all stocks mentioned..

SUBSCRIPTION INFORMATION:

1 YEAR HARD COPY $250.00

1 YEAR PERSONAL CONVERSATION WITH EDITOR $3000.00- ANYTIME ACCESS VIA PHONE

$1800.00 ANYTIME ACCESS VIA PHONE FOR 6 MONTHS- CALL FOR INFORMATION- WE CALL YOU AND YOU CAN CALL US+ FIRST CALL ON RECOMMENDATIONS PRIOR TO ALL OTHERS.

1 TRIAL "NEW" STOCK PICK BEFORE RELEASED VIA EMAIL $100.00- INCLUDE PHONE NUMBER.

SEND CHECK: S A ADVISORY, 4708 S HOLLADAY BLVD, SALT CITY, UTAH 84117

QUESTIONS 949 922 9986




[http://img.constantcontact.com/letters/images/business-right-corner.gif]